Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 4.29 EUR -6.94% Market Closed
Market Cap: 120.1m EUR
Have any thoughts about
Hyloris Pharmaceuticals SA?
Write Note

Relative Value

The Relative Value of one HYL stock under the Base Case scenario is 4.67 EUR. Compared to the current market price of 4.29 EUR, Hyloris Pharmaceuticals SA is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HYL Relative Value
Base Case
4.67 EUR
Undervaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
74
vs Industry
4
Median 3Y
157
Median 5Y
139.3
Industry
2.6
Forward
14.5
vs History
vs Industry
Median 3Y
-27.3
Median 5Y
-33.5
Industry
23
Forward
-7.9
vs History
vs Industry
Median 3Y
-29
Median 5Y
-31.1
Industry
17.8
vs History
vs Industry
Median 3Y
-23.4
Median 5Y
-25.3
Industry
25.4
vs History
96
vs Industry
8
Median 3Y
7
Median 5Y
6.6
Industry
2.2
vs History
74
vs Industry
4
Median 3Y
139.6
Median 5Y
123.1
Industry
2.8
Forward
11.1
vs History
74
vs Industry
2
Median 3Y
148.6
Median 5Y
127.5
Industry
5.4
vs History
vs Industry
Median 3Y
-24
Median 5Y
-32.5
Industry
13.7
Forward
-6
vs History
vs Industry
Median 3Y
-23.6
Median 5Y
-30.6
Industry
17.2
Forward
-6.1
vs History
vs Industry
Median 3Y
-26
Median 5Y
-27.1
Industry
16.5
vs History
vs Industry
Median 3Y
-24.3
Median 5Y
-26.1
Industry
19.3
vs History
96
vs Industry
5
Median 3Y
23.2
Median 5Y
30.9
Industry
2

Multiples Across Competitors

HYL Competitors Multiples
Hyloris Pharmaceuticals SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Hyloris Pharmaceuticals SA
XBRU:HYL
123.8m EUR 57.6 -7.8 -6.1 -6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
761.8B USD 18.5 90.9 48.9 54.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
368.4B USD 4.2 25 12.1 15.8
US
Merck & Co Inc
NYSE:MRK
250.9B USD 4 20.6 10.4 12.5
CH
Roche Holding AG
SIX:ROG
208.8B CHF 3.6 18.2 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP 4.1 31.3 169.3 253.7
IE
Endo International PLC
LSE:0Y5F
155B USD 66.9 -53 248.3 622.6
P/E Multiple
Earnings Growth
BE
Hyloris Pharmaceuticals SA
XBRU:HYL
Average P/E: 33.4
Negative Multiple: -7.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25
-22%
US
Merck & Co Inc
NYSE:MRK
20.6
7 336%
CH
Roche Holding AG
SIX:ROG
18.2
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.3
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -53 N/A

See Also

Discover More
Back to Top